PortalPublikationenClinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion f...

Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities

Standard

Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities. / Stolzenbach, Lara Franziska; Löcherbach, Florian; Wargenau, Katharina; Pose, Randi; Steuber, Thomas; Tian, Zhe; Budäus, Lars; Tilki, Derya; Graefen, Markus; Köhler, Daniel; Karakiewicz, Pierre I; Sauer, Markus; Apostolova, Ivayla Ilieva; Maurer, Tobias; Berliner, Christoph.

in: NUKLEARMED-NUCL MED, Jahrgang 60, Nr. 6, 12.2021, S. 417-424.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Stolzenbach, LF, Löcherbach, F, Wargenau, K, Pose, R, Steuber, T, Tian, Z, Budäus, L, Tilki, D, Graefen, M, Köhler, D, Karakiewicz, PI, Sauer, M, Apostolova, II, Maurer, T & Berliner, C 2021, 'Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities', NUKLEARMED-NUCL MED, Jg. 60, Nr. 6, S. 417-424. https://doi.org/10.1055/a-1542-6064

APA

Stolzenbach, L. F., Löcherbach, F., Wargenau, K., Pose, R., Steuber, T., Tian, Z., Budäus, L., Tilki, D., Graefen, M., Köhler, D., Karakiewicz, P. I., Sauer, M., Apostolova, I. I., Maurer, T., & Berliner, C. (2021). Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities. NUKLEARMED-NUCL MED, 60(6), 417-424. https://doi.org/10.1055/a-1542-6064

Vancouver

Stolzenbach LF, Löcherbach F, Wargenau K, Pose R, Steuber T, Tian Z et al. Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities. NUKLEARMED-NUCL MED. 2021 Dez;60(6):417-424. https://doi.org/10.1055/a-1542-6064

Bibtex

@article{f71328bd0438465199b9b8dcf3443466,
title = "Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities",
abstract = "AIM: Few small-scaled studies performed systematic analysis of the benefits of extending prostate specific membrane antigen positron-emission tomography/ computed tomography (68Ga-PSMA I&T PET/CT) to the lower extremities in prostate cancer (PCa) patients. We hypothesized that 68Ga-PSMA I&T PET/CT positive lesions are rare in lower extremities of prostate cancer (PCa) patients, the clinical implication is negligible and may therefore be omitted.METHODS: We retrospectively analyzed 1,068 PCa patients who received 68Ga-PSMA I&T PET/CT in a single institution (2016-2018). Of those, 285 (26.7%) were newly diagnosed, 529 (49.5%) had biochemical recurrence (BCR) and 254 (23.8%) were castration-resistant prostate cancer (CRPC) patients.RESULTS: Of 1,068 68Ga-PSMA I&T PET/CTs, positive lesions in the lower extremities were identified in 6.9% patients (n=74). Positive lesions in the lower extremities were most common in CRPC patients (19.7%; n=50), followed by newly diagnosed (3.2%; n=9) and BCR (2.8%; n=15) PCa patients. Only 3 patients presented with exclusive lesions in the lower extremities, respectively 0.8% (n=2) in CRPC and 0.4% (n=1) in newly diagnosed PCa. Both CRPC (94.1%, n=47) and BCR (80.0%, n=12) patients with PSMA-positive lesions predominantly received systemic therapy.CONCLUSION: Identification of lower extremities lesions with PSMA PET/CT is uncommon and exclusive lesions are rare. PSMA PET/CT findings of the lower extremities did not change therapy management. Thus, scanning of the lower extremities can be omitted in standard protocols.",
keywords = "Gallium Isotopes, Gallium Radioisotopes, Humans, Lower Extremity, Male, Positron Emission Tomography Computed Tomography, Retrospective Studies",
author = "Stolzenbach, {Lara Franziska} and Florian L{\"o}cherbach and Katharina Wargenau and Randi Pose and Thomas Steuber and Zhe Tian and Lars Bud{\"a}us and Derya Tilki and Markus Graefen and Daniel K{\"o}hler and Karakiewicz, {Pierre I} and Markus Sauer and Apostolova, {Ivayla Ilieva} and Tobias Maurer and Christoph Berliner",
note = "Thieme. All rights reserved.",
year = "2021",
month = dec,
doi = "10.1055/a-1542-6064",
language = "English",
volume = "60",
pages = "417--424",
journal = "NUKLEARMED-NUCL MED",
issn = "0029-5566",
publisher = "Schattauer",
number = "6",

}

RIS

TY - JOUR

T1 - Clinical impact of whole-body 68Ga-PSMA I&T PET/CT: lesion frequency and added benefit in lower extremities

AU - Stolzenbach, Lara Franziska

AU - Löcherbach, Florian

AU - Wargenau, Katharina

AU - Pose, Randi

AU - Steuber, Thomas

AU - Tian, Zhe

AU - Budäus, Lars

AU - Tilki, Derya

AU - Graefen, Markus

AU - Köhler, Daniel

AU - Karakiewicz, Pierre I

AU - Sauer, Markus

AU - Apostolova, Ivayla Ilieva

AU - Maurer, Tobias

AU - Berliner, Christoph

N1 - Thieme. All rights reserved.

PY - 2021/12

Y1 - 2021/12

N2 - AIM: Few small-scaled studies performed systematic analysis of the benefits of extending prostate specific membrane antigen positron-emission tomography/ computed tomography (68Ga-PSMA I&T PET/CT) to the lower extremities in prostate cancer (PCa) patients. We hypothesized that 68Ga-PSMA I&T PET/CT positive lesions are rare in lower extremities of prostate cancer (PCa) patients, the clinical implication is negligible and may therefore be omitted.METHODS: We retrospectively analyzed 1,068 PCa patients who received 68Ga-PSMA I&T PET/CT in a single institution (2016-2018). Of those, 285 (26.7%) were newly diagnosed, 529 (49.5%) had biochemical recurrence (BCR) and 254 (23.8%) were castration-resistant prostate cancer (CRPC) patients.RESULTS: Of 1,068 68Ga-PSMA I&T PET/CTs, positive lesions in the lower extremities were identified in 6.9% patients (n=74). Positive lesions in the lower extremities were most common in CRPC patients (19.7%; n=50), followed by newly diagnosed (3.2%; n=9) and BCR (2.8%; n=15) PCa patients. Only 3 patients presented with exclusive lesions in the lower extremities, respectively 0.8% (n=2) in CRPC and 0.4% (n=1) in newly diagnosed PCa. Both CRPC (94.1%, n=47) and BCR (80.0%, n=12) patients with PSMA-positive lesions predominantly received systemic therapy.CONCLUSION: Identification of lower extremities lesions with PSMA PET/CT is uncommon and exclusive lesions are rare. PSMA PET/CT findings of the lower extremities did not change therapy management. Thus, scanning of the lower extremities can be omitted in standard protocols.

AB - AIM: Few small-scaled studies performed systematic analysis of the benefits of extending prostate specific membrane antigen positron-emission tomography/ computed tomography (68Ga-PSMA I&T PET/CT) to the lower extremities in prostate cancer (PCa) patients. We hypothesized that 68Ga-PSMA I&T PET/CT positive lesions are rare in lower extremities of prostate cancer (PCa) patients, the clinical implication is negligible and may therefore be omitted.METHODS: We retrospectively analyzed 1,068 PCa patients who received 68Ga-PSMA I&T PET/CT in a single institution (2016-2018). Of those, 285 (26.7%) were newly diagnosed, 529 (49.5%) had biochemical recurrence (BCR) and 254 (23.8%) were castration-resistant prostate cancer (CRPC) patients.RESULTS: Of 1,068 68Ga-PSMA I&T PET/CTs, positive lesions in the lower extremities were identified in 6.9% patients (n=74). Positive lesions in the lower extremities were most common in CRPC patients (19.7%; n=50), followed by newly diagnosed (3.2%; n=9) and BCR (2.8%; n=15) PCa patients. Only 3 patients presented with exclusive lesions in the lower extremities, respectively 0.8% (n=2) in CRPC and 0.4% (n=1) in newly diagnosed PCa. Both CRPC (94.1%, n=47) and BCR (80.0%, n=12) patients with PSMA-positive lesions predominantly received systemic therapy.CONCLUSION: Identification of lower extremities lesions with PSMA PET/CT is uncommon and exclusive lesions are rare. PSMA PET/CT findings of the lower extremities did not change therapy management. Thus, scanning of the lower extremities can be omitted in standard protocols.

KW - Gallium Isotopes

KW - Gallium Radioisotopes

KW - Humans

KW - Lower Extremity

KW - Male

KW - Positron Emission Tomography Computed Tomography

KW - Retrospective Studies

U2 - 10.1055/a-1542-6064

DO - 10.1055/a-1542-6064

M3 - SCORING: Journal article

C2 - 34416785

VL - 60

SP - 417

EP - 424

JO - NUKLEARMED-NUCL MED

JF - NUKLEARMED-NUCL MED

SN - 0029-5566

IS - 6

ER -